Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairment
Status:
Recruiting
Trial end date:
2022-02-15
Target enrollment:
Participant gender:
Summary
The main purpose of the study is to evaluate the pharmacokinetics (PK) of a single oral dose
of sotorasib administered in participants with moderate or severe hepatic impairment compared
to participants with normal hepatic function.